Related Experiment Video
Updated: Aug 13, 2026
A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies
Published on: September 23, 2014
Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry
Y Natkunam1, R A Warnke, K Montgomery
1Department of Pathology, Stanford University Medical Center, Stanford, California 94305, USA. ynatkunam@yahoo.com
Abstract:
The gene encoding MUM1 was characterized as a possible translocation partner in chromosomal abnormalities involving a significant number of multiple myelomas. The overexpression of the MUM1 protein as a result of translocation t(6;14) (p25;q32) identified MUM1 as a putative regulatory molecule involved in B-cell differentiation and tumorigenesis. The expression of MUM1 protein in multiple myelomas supports this hypothesis. In the current study, using tissue microarray technology, we have tested the expression of the MUM1 protein in 1335 human malignancies and normal tissues. Our data show that the MUM1 protein is expressed in a wide spectrum of hematolymphoid neoplasms and in malignant melanomas but is absent in other human tumors. In addition, in tissue microarrays as well as in conventional paraffin sections, MUM1 staining was found to lack specificity in detecting plasmacytic differentiation as compared with two markers, CD138/Syndecan and VS38, commonly used in paraffin immunohistochemistry for detection of plasma cells.
Insights
MUM1 protein is found in hematolymphoid neoplasms and melanomas, but not other cancers. MUM1 lacks specificity for plasma cell detection compared to CD138 and VS38 markers.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The gene encoding MUM1 was identified as a translocation partner in multiple myelomas.
- MUM1 protein overexpression, due to translocation t(6;14), suggests its role in B-cell differentiation and tumorigenesis.
- Previous findings indicated MUM1 protein expression in multiple myelomas, supporting its oncogenic hypothesis.
Purpose of the Study:
- To investigate the expression profile of MUM1 protein across a broad range of human malignancies and normal tissues.
- To evaluate the diagnostic specificity of MUM1 in detecting plasmacytic differentiation.
Main Methods:
- Tissue microarray technology was employed to analyze MUM1 protein expression.
- A comprehensive analysis of 1335 human malignancies and normal tissues was conducted.
- MUM1 staining specificity was compared with established plasma cell markers (CD138/Syndecan and VS38) using immunohistochemistry on paraffin-embedded tissues.
Main Results:
- MUM1 protein expression was detected in a diverse array of hematolymphoid neoplasms and malignant melanomas.
- MUM1 protein was notably absent in other tested human tumor types.
- MUM1 staining demonstrated a lack of specificity in identifying plasmacytic differentiation when contrasted with CD138/Syndecan and VS38.
Conclusions:
- MUM1 protein expression is restricted to specific hematolymphoid neoplasms and melanomas.
- MUM1 is not a universally applicable marker for all human tumors.
- CD138/Syndecan and VS38 remain more specific markers for plasma cell detection in paraffin immunohistochemistry than MUM1.
